Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
复制标题
DOI：
10.1002/cncr.33141
复制
发表时间：
2020-12-01
期刊：
影响因子：
6.2
通讯作者：
Owonikoko TK
中科院分区：
文献类型：
--
作者：
Nazha B;Goyal S;Chen Z;Engelhart A;Carlisle JW;Beardslee TJ;Gill H;Odikadze L;Liu Y;Mishra MK;Ramalingam SS;Owonikoko TK
由于关键性试验中少数族裔背景患者的代表性不足，尚未研究晚期NSCLC疗效的种族差异。我们探讨了不同患者人群中结果的真实差异。我们回顾性分析了2013年至2018年7月在埃默里大学Winship癌症研究所接受单药免疫检查点阻断（ICB）治疗的晚期NSCLC患者的临床结局。通过对总生存期（OS）和无进展生存期（PFS）进行双变量和多变量分析，对黑人和白人进行主要疗效比较。257例患者中位年龄69岁，女性占50.6%，白人（W）/黑人（B）/其他种族分别占63.4%/29.5%/7.1%。ICB一线51例（19.9%），二线161例（62.9%），三线33例（12.9%）。最常用的药物为纳武单抗（49.0%）、派姆单抗（25.2%）和atezolizumab（21.3%）。观察到B和W之间的OS（p=0.839）和PFS（p=0.235）无差异。样本ORR为20.6% - 15.2% B，W为23.1%。未观察到女性和男性之间的OS（p=0.0812）和PFS（p=0.176）差异。B组和W组的免疫相关不良事件（irAE）发生率相似（20.0% vs. 29.9%，P值=0.148）。在多变量分析中，种族与OS或PFS无显著相关性。我们机构经验的真实世界分析显示，ICB在黑人与白色晚期NSCLC患者中的疗效和耐受性相似。更大的多机构研究，包括其他美国少数民族人口将使我们的研究结果具有普遍性。我们对2013年至2018年间在佐治亚州亚特兰大接受单药免疫检查点阻断治疗的非小细胞肺癌患者的总生存期（OS）和无进展生存期（PFS）进行了一项回顾性研究。我们的数据显示，黑人和白人在OS、PFS和免疫相关不良事件发生率方面的结局相似。需要进行大规模的研究，使我们的发现更具普遍性。
Race-based differences in efficacy for advanced NSCLC have not been studied due to under-representation of patients of minority background in pivotal trials. We explored real-world differences in outcome in our diverse patient population. We retrospectively analyzed clinical outcomes of patients with advanced NSCLC treated with single-agent immune checkpoint blockade (ICB) between 2013 and July 2018 at Winship Cancer Institute of Emory University. Primary efficacy comparison between Blacks and Whites was performed by bivariate and multivariate analyses for overall survival (OS) and progression free survival (PFS). We analyzed data from 257 patients: The median age was 69 years old, 50.6% were female, Whites (W) /Blacks (B)/Other race made up 63.4%/29.5%/7.1% respectively. ICB was 1st line in 51 (19.9%), 2nd line in 161 (62.9%), 3rd line in 33 (12.9%). The most commonly used agents were nivolumab (49.0%), pembrolizumab (25.2%) and atezolizumab (21.3%). No difference in OS (p=0.839) and PFS (p=0.235) between B and W were seen. The sample ORR was 20.6% - 15.2% B and 23.1% for W. No differences in OS (p=0.0812) and PFS (p=0.176) between females and males were seen. The rate of immune-related adverse events (irAE) was similar in B and W (20.0% vs. 29.9%, P-value=0.148). On multivariate analysis, race was not significantly associated with OS or PFS. Real-world analysis of our institutional experience showed similar efficacy and tolerability of ICB in Black vs White advanced NSCLC patients. Larger multi-institutional studies to include other US minority populations would make our findings generalizable. We performed a retrospective study of overall survival (OS) and progression free survival (PFS) of non-small cell lung cancer patients treated with single agent immune checkpoint blockade in Atlanta, GA between 2013 to 2018. Our data shows similar outcomes between Blacks and Whites in terms of OS, PFS, and rate of immune-related adverse events. Large studies are needed to make our findings more generalizable.
登录
查看更多内容
影响因子：
7.4
作者：
Geller, Stacie E.;Koch, Abigail R.;Carnes, Molly
通讯作者：
Carnes, Molly
DOI：
10.1016/s0140-6736(16)32517-x
发表时间：
2017-01-21
期刊：
Lancet (London, England)
影响因子：
--
作者：
Rittmeyer A;Barlesi F;Waterkamp D;Park K;Ciardiello F;von Pawel J;Gadgeel SM;Hida T;Kowalski DM;Dols MC;Cortinovis DL;Leach J;Polikoff J;Barrios C;Kabbinavar F;Frontera OA;De Marinis F;Turna H;Lee JS;Ballinger M;Kowanetz M;He P;Chen DS;Sandler A;Gandara DR;OAK Study Group
通讯作者：
OAK Study Group
影响因子：
28.4
作者：
O'Connor, Jeremy M.;Fessele, Kristen L.;Gross, Cary P.
通讯作者：
Gross, Cary P.
DOI：
10.1200/edbk_100021
发表时间：
2019-01-01
期刊：
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
影响因子：
--
作者：
Nazha, Bassel;Mishra, Manoj;Owonikoko, Taofeek K
通讯作者：
Owonikoko, Taofeek K
影响因子：
6.2
作者：
Aizer, Ayal A.;Wilhite, Tyler J.;Nguyen, Paul L.
通讯作者：
Nguyen, Paul L.